Herrstedt, J. (2008). Antiemetics: An update and the MASCC guidelines applied in clinical practice. Nature Clinical Practice.Oncology, 5, 32–43.doi: 10.1038/ncponc1021
To review the pathophysiology of cancer-related nausea and vomiting and the research regarding various medications for management of this symptom, as well as similarities and differences among guidelines of various professional groups
Multinational Association of Supportive Care in Cancer (MASCC) guidelines are based on consensus via surveys and a consensus conference.
High emetic risk (e.g., cisplatin, dacarbazine, high-dose cyclophosphamide)
Moderate emetic risk (e.g., cyclophosphamide at more than 100 mg/m2, anthracyclines, oxaliplatin, carboplatin)
Low emetic risk (e.g., topotecan, gemcitabine, taxanes, capecitabine, trastuzumab)
Minimal emetic risk (e.g., bleomycin, vinca-alkaloids, bevacizumab): No routine prophylaxis
No approach to anticipatory nausea was provided.
New medications are highly effective in prophylaxis of emesis, but prevention of nausea remains challenging.